Platelet Function Testing and Antiplatelet Management in Patients with Recurrent Ischemic Stroke

Guideline Position on Platelet Function Testing

The 2021 American Heart Association/American Stroke Association (AHA/ASA) stroke‑prevention guideline states that routine pharmacologic responsiveness testing to antiplatelet therapy has no Class I or IIa recommendation for long‑term stroke prevention; its utility remains unclear. 1
Routine P2Y12 platelet‑function testing is not recommended for guiding antiplatelet therapy in patients with recurrent ischemic stroke because current guidelines do not support its use. 1
No randomized‑controlled trial evidence exists for platelet‑function‑guided therapy in stroke populations, and the evidence base is limited to coronary‑intervention studies, which cannot be extrapolated to cerebrovascular disease. Evidence level: absent RCT data. 1

Continue aspirin + clopidogrel for the full 21–90 day course after a recurrent stroke that occurs during the acute DAPT window. Evidence level: guideline‑based recommendation. 1
If a recurrent stroke occurs while on single antiplatelet therapy (SAPT), start DAPT immediately (aspirin + clopidogrel within 24–72 h for minor stroke or high‑risk TIA). Evidence level: expert summary (Praxis Medical Insights). 2
Monitor for bleeding complications, especially in patients ≥ 70 years, who have a markedly higher risk of intracranial hemorrhage. Evidence level: expert summary (Praxis Medical Insights). 2

After 21–90 days of DAPT, switch to lifelong SAPT; extending DAPT beyond 90 days provides no additional stroke protection and increases hemorrhage risk. Evidence level: guideline‑based recommendation. 1
When the recurrent event occurred on SAPT, switch to a different antiplatelet agent; meta‑analysis shows a 30 % relative risk reduction (hazard ratio 0.70). Evidence level: moderate‑quality (meta‑analysis). 1
Preferred SAPT options:
Evidence level: expert summary (Praxis Medical Insights). 2

Do not extend DAPT beyond 90 days based on platelet‑function test results; intracranial hemorrhage risk begins to outweigh benefits as early as the 21‑ to 90‑day period. Evidence level: guideline‑based recommendation. 1
Do not use platelet‑function testing to justify continuing ineffective therapy; if a recurrent stroke occurs on antiplatelet therapy, the evidence supports switching agents rather than dose escalation. Evidence level: guideline‑based recommendation. 1

CYP2C19 genotyping is not recommended for routine practice; although it may have predictive value comparable to acute PRU testing for identifying poor metabolizers at highest risk of early recurrence, it remains a research tool and is not incorporated into current guidelines. Evidence level: guideline‑based statement (no recommendation). 1